The US Department of Defense Awarded Contract to SIGA for Expanded Indication of TPOXX (tecovirimat) for $19.5M

 The US Department of Defense Awarded Contract to SIGA for Expanded Indication of TPOXX (tecovirimat) for $19.5M

The US Department of Defense Awarded Contract to SIGA for Expanded Indication of TPOXX (tecovirimat) for $19.5M

Shots:

  • SIGA to receive $12.4M as upfront with total value $19.5M to support clinical & regulatory activities of TPOXX (tecovirimat) in its evaluation as post-exposure prophylactic to treat smallpox symptomatic infection and patients with known smallpox exposure with no developed symptoms for smallpox
  • The expanded indication of TPOXX provides flexibility to deliver TPOXX to those who might benefit from treatment during a potential outbreak. Additionally, SIGA is also working with U.S. Army Medical Research Institute of Infectious Disease on animal studies to evaluate TPOXX as PEP for smallpox
  • TPOXX (PO, IV) is an anti-viral therapy, indicated to treat smallpox to mitigate the impact of a potential outbreak or bioterror attack and its oral formulation has received FDA’s Approval on Jul 13, 2018

Click here to read full press release/ article | Ref: SIGA | Image: EC-Council

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post